Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients

Neurology

Volumn 76, Issue 16, 2011, Pages 1403-1409

  Ciccarelli, N ^a,b   Fabbiani, M ^a   Di Giambenedetto, S ^a   Fanti, I ^a   Baldonero, E ^a   Bracciale, L ^a   Tamburrini, E ^a   Cauda, R ^a   De Luca, A ^a   Silveri, M C ^b  

^a Institute of Clinical Infectious Diseases   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EFAVIRENZ; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; EDUCATION; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; PREVALENCE; PRIORITY JOURNAL; STROOP TEST;

ACTIVITIES OF DAILY LIVING; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79955458684     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31821670fb     Document Type: Article

References (29)

1. Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990-1998. Neurology 2001;56:257-260. (Pubitemid 32095372)
2. McArthur JC. HIV Dementia: an evolving disease. J Neuroimmunol 2004;157:3-10. (Pubitemid 39576633)
3. Brew B, Crowe SM, Landay A, Cysique LA, Guillemin G. Neurodegeneration and aging in the HAART era. J Neuroimmune Pharmacol 2009;4:163-174.
4. Cysique LA, Brew B. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 2009;19:169-185.
5. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65-70.
6. Koopmans PP, Ellis R, Best BM, Letendre S. Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration? Netherlands J Med 2009;67:206-211.
7. Letendre S, FitzSimons C, Ellis R. Correlates of CSF viral loads in 1221 volunteers of the CHARTER Cohort [abstract 172]. Presented at the 17th Conference on Retrovirus and Opportunistic Infections, February 16-19, 2010, San Francisco.
8. Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 2004;61:1699-1704. (Pubitemid 39463428)
9. Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009;73:342-348.
10. Tozzi V, Balestra P, Salvatori MF, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009;52:56-63.
11. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychological deficits despite long-term HAART in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007;45:174-182. (Pubitemid 46869810)
12. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009;23: 1359-1366.
13. Simeoni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010;24:1243-1250.
14. Staszewski J, Morales-Ramirez KT, Tashima AR, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults: Study 006 Team. N Engl J Med 1999;341:1865-1873.
15. US Department of Health and Human Services. Panel on Clinical Practices for the Treatment of HIV Infection: Guidelines for the use of Antiretroviral Agents to HIVInfected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2005.
16. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001;15:71-75. (Pubitemid 32055781)
17. Rihs TA, Begley K, Smith DE, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med 2006;7:544-548. (Pubitemid 44742355)
18. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005;143: 714-721.
19. Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials 2009;10:343-355.
20. Lovibond SH, Lovibond PF. Manual for Depression Anxiety Stress Scales, 2nd ed. Sydney, Australia: Psychology Foundation; 1995.
21. Capitani E, Laiacona M. Composite neuropsychological batteries and demographic correction: standardization based on equivalent scores, with a review of published data: The Italian Group for the Neuropsychological Study of Ageing. J Clin Exp Neuropsychol 1997;19: 795-809. (Pubitemid 28153409)
22. Antinori A, Arendt G, Becker JT, et al. Update research for HIV-associated neurocognitive disorders. Neurology 2007;69:1789-1799. (Pubitemid 350059308)
23. Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 2009;19:152-168.
24. Heaton RK, Clifford DB, Franklin DR, et al. HIVassociated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75:2087-2096.
25. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 2004;10:350-357. (Pubitemid 40109622)
26. Winston A, Duncombe C, Li PC, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cere- bral function testing after 48 weeks in treatment-naïve, HIV-1 infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 2010;50:920-929.
27. Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010;74: 1260-1266.
28. Liner J, Meeker RB, Robertson K. CNS toxicity of antiretroviral drugs [abstract 435]. Presented at the 17th Conference on Retrovirus and Opportunistic Infections, February 16-19, 2010, San Francisco.
29. Robertson K, Liner J, Heaton R. Neuropsychological assessment of HIV-infected populations in international settings. Neuropsychol Rev 2009;19:232-249.